편두통약 시장 : 약제 클래스별, 투여 경로별, 유형별, 유통 채널별 - 세계 예측(2024-2032년)

Global Migraine Drugs Market size is anticipated to witness 6.7% CAGR from 2024 to 2032, due to the increasing awareness for improved diagnosis alongside advancements in drug development.

Lately, several individuals are seeking medical attention and receiving accurate diagnoses, leading to greater demand for effective treatments. Concurrently, researchers are developing new migraine drugs by incorporating advancements in pharmacology and technology to enhance treatment options. These innovations are improving drug efficacy while reducing side effects and providing more targeted therapies. For instance, in January 2024, Akums launched the Lasmiditan tablet to alleviate migraine symptoms to enhance treatment options for providing a targeted approach to managing migraines and improving patient outcomes with advanced therapeutic benefits.

The migraine drugs market is segregated into drug class, route of administration, type, distribution channel, and region.

By drug class, the preventive medication segment is estimated to rise at a significant CAGR from 2024 to 2032 due to the strong requirement to reduce the frequency and severity of migraine attacks before they occur. Preventive medications are developed and prescribed to manage chronic migraines and prevent debilitating episodes. They work by targeting underlying mechanisms that trigger migraines, thereby decreasing the overall occurrence and impact of attacks. Additionally, the ongoing research and technological advancements are refining preventive treatments for more effective and tailored options for individuals with chronic migraines.

Migraine drugs industry value from the online pharmacies distribution channel segment is expected to expand from 2024 to 2032, fueled by the increasing need for offering greater convenience and accessibility for patients. These platforms are providing a range of migraine medications, including both prescription and over-the-counter options, further allowing users to easily order and receive their treatments from home. The growing adoption of online pharmacies is also making it simpler for individuals to access their medications promptly and manage their treatment plans more effectively.

Regionally, the Europe migraine drugs industry size is projected to proliferate between 2024 and 2032, led by rising healthcare expenditure along with increased awareness and diagnosis of migraine disorders. Companies are investing in advanced treatments to support individuals experiencing migraines. Simultaneously, the heightened awareness and better diagnostic practices are leading to more accurate diagnoses and greater demand for effective migraine therapies in the region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360º synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence and prevalence of migraine
    • 3.2.1.2 Rising patient preference for non-invasive treatment
    • 3.2.1.3 Growing awareness and diagnosis of migraine
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory requirements
    • 3.2.2.2 Competition from alternative treatments
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Pricing analysis
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Million)

• 5.1 Key trends
• 5.2 Pain relieving medication
  • 5.2.1 Triptans
  • 5.2.2 Analgesics
  • 5.2.3 Ditans
  • 5.2.4 Other pain-relieving medications
• 5.3 Prescription medication
  • 5.3.1 Anticonvulsant
  • 5.3.2 Antidepressant
  • 5.3.3 Beta blocker
  • 5.3.4 CGRP inhibitors
  • 5.3.5 Other preventive medications

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Million)

• 6.1 Key trends
• 6.2 Oral
• 6.3 Injectable
• 6.4 Nasal
• 6.5 Transdermal

Chapter 7 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Million)

• 7.1 Key trends
• 7.2 Prescription drugs
• 7.3 OTC drugs

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Million)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Drug store & retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 AbbVie Inc.
• 10.2 Amgen, Inc.
• 10.3 Astellas Pharma
• 10.4 AstraZeneca Plc
• 10.5 Azurity Pharmaceutical, Inc.
• 10.6 Dr. Reddy's Laboratories, Inc.
• 10.7 Eli Lilly and Company
• 10.8 Endo Pharmaceuticals, Inc.
• 10.9 GlaxoSmithKline Plc
• 10.10 Lannett Company, Inc.
• 10.11 Lundbeck A/S
• 10.12 Pfizer, Inc.
• 10.13 Sanofi SA
• 10.14 Sun Pharmaceutical Industries Limited
• 10.15 Teva Pharmaceutical Industries Limited